Conditional survival analysis of patients with resected non-small cell lung cancer

被引:0
作者
Chaudhry, Talib [1 ]
Krishnan, Vaishnavi [1 ]
Donaldson, Andrew E. [1 ]
Palmisano, Zachary M. [1 ]
Basu, Sanjib [1 ]
Geissen, Nicole M. [1 ]
Karush, Justin M. [1 ]
Alex, Gillian C. [1 ]
Borgia, Jeffrey A. [2 ,3 ]
Liptay, Michael J. [1 ]
Seder, Christopher W. [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Cardiovasc & Thorac Surg, Joan & Paul Rubschlager Bldg,6th Floor,1520 W Harr, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL USA
[3] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL USA
关键词
non-small cell lung cancer; conditional sur- vival; conditional survival; prognosis; LONG-TERM SURVIVAL; RECURRENCE; PROBABILITY;
D O I
10.1016/j.xjon.2023.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Conditional survival (CS) analyses provide an estimate of survival accounting for years already survived after treatment. We aim to evaluate the difference between actuarial and conditional survival in patients following lung resection for non-small - small cell lung cancer (NSCLC). In addition, CS analyses are used to examine whether prognosticators of survival change over time following surgery. Methods: Patients who underwent anatomic lung resection at a single institution for pathologic stage I-IIIA NSCLC between 2010 and 2021 were identified; those who underwent wedge resection for node-negative tumors < 2 cm were also included. CS estimates were calculated as the probability of remaining disease- free after x years of nonrecurrence (CSx). Kaplan-Meier, log-rank, and Cox proportional hazard methods for examining CS were used for subgroup comparisons and assessing associations with baseline covariates. Results: Overall, 863 patients met the study inclusion criteria, with a median followup of 44.1 months. Conditional overall survival (OS) and disease-free survival (DFS) were greater than actuarial rates at all time points after surgery. At the time of resection, male sex (hazard ratio [HR], 1.33; 95% % confidence interval [CI], 1.03 to 1.72; P = .032), tumor size>3 cm (HR, 1.17; 95% % CI, 1.11-1.23; P < .001), node positivity (HR, 3.31; 95% % CI, 2.52-4.33; P < .001), and American Joint Committee on Cancer stage (P < .001) were associated with DFS. However, if a patient lived 3 years without recurrence (CS3), these factors were no longer prognostic of DFS. Conclusions: Conditional survival analyses provide dynamic assessments of OS and DFS after NSCLC resection. After 3 years without recurrence, certain characteristics associated with DFS at the time of surgery no longer prognosticate recurrence. (JTCVS Open 2023;16:948-59)
引用
收藏
页码:948 / 959
页数:12
相关论文
共 28 条
[1]   Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503) [J].
Altorki, Nasser K. ;
Wang, Xiaofei ;
Wigle, Dennis ;
Gu, Lin ;
Darling, Gail ;
Ashrafi, Ahmad S. ;
Landrenau, Rodney ;
Miller, Daniel ;
Liberman, Moishe ;
Jones, David R. ;
Keenan, Robert ;
Conti, Massimo ;
Wright, Gavin ;
Veit, Linda J. ;
Ramalingam, Suresh S. ;
Kamel, Mohamed ;
Pass, Harvey I. ;
Mitchell, John D. ;
Stinchcombe, Thomas ;
Vokes, Everett ;
Kohman, Leslie J. .
LANCET RESPIRATORY MEDICINE, 2018, 6 (12) :915-924
[2]  
American Lung Association, Key statistics for lung cancer. How common is lung cancer?
[3]   Conditional Relative Survival of Cancer Patients and Conditional Probability of Death [J].
Bouvier, Anne-Marie ;
Remontet, Laurent ;
Hedelin, Guy ;
Launoy, Guy ;
Jooste, Valerie ;
Grosclaude, Pascale ;
Belot, Aurelien ;
Lacour, Brigitte ;
Esteve, Jacques ;
Bossard, Nadine ;
Faivre, Jean .
CANCER, 2009, 115 (19) :4616-4624
[4]   Timing of Local and Distant Failure in Resected Lung Cancer Implications for Reported Rates of Local Failure [J].
Boyd, Jessamy A. ;
Hubbs, Jessica L. ;
Kim, Dong W. ;
Hollis, Donna ;
Marks, Lawrence B. ;
Kelsey, Chris R. .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) :211-214
[5]   Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report [J].
Chiu, CH ;
Chern, MS ;
Wu, MH ;
Hsu, WH ;
Wu, YC ;
Huang, MH ;
Chang, SC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (06) :1300-1305
[6]   Conditional survival rate estimates of lobectomy, segmentectomy and wedge resection for stage IA1 non-small cell lung cancer: A population-based study [J].
Fan, Xiaoxi ;
Liang, Yicheng ;
Bai, Yunpeng ;
Yang, Chunlu ;
Xu, Shun .
ONCOLOGY LETTERS, 2020, 20 (02) :1607-1618
[7]   Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].
Felip, Enriqueta ;
Altorki, Nasser ;
Zhou, Caicun ;
Csoszi, Tibor ;
Vynnychenko, Ihor ;
Goloborodko, Oleksandr ;
Luft, Alexander ;
Akopov, Andrey ;
Martinez-Marti, Alex ;
Kenmotsu, Hirotsugu ;
Chen, Yuh-Min ;
Chella, Antonio ;
Sugawara, Shunichi ;
Voong, David ;
Wu, Fan ;
Yi, Jing ;
Deng, Yu ;
McCleland, Mark ;
Bennett, Elizabeth ;
Gitlitz, Barbara ;
Wakelee, Heather .
LANCET, 2021, 398 (10308) :1344-1357
[8]   Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].
Forde, Patrick M. ;
Spicer, Jonathan ;
Lu, Shun ;
Provencio, Mariano ;
Mitsudomi, Tetsuya ;
Awad, Mark M. ;
Felip, Enriqueta ;
Broderick, Stephen R. ;
Brahmer, Julie R. ;
Swanson, Scott J. ;
Kerr, Keith ;
Wang, Changli ;
Ciuleanu, Tudor-Eliade ;
Saylors, Gene B. ;
Tanaka, Fumihiro ;
Ito, Hiroyuki ;
Chen, Ke-Neng ;
Liberman, Moishe ;
Vokes, Everett E. ;
Taube, Janis M. ;
Dorange, Cecile ;
Cai, Junliang ;
Fiore, Joseph ;
Jarkowski, Anthony ;
Balli, David ;
Sausen, Mark ;
Pandya, Dimple ;
Calvet, Christophe Y. ;
Girard, Nicolas .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985
[9]   Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer [J].
Fukui, Takayuki ;
Okasaka, Toshiki ;
Kawaguchi, Koji ;
Fukumoto, Koichi ;
Nakamura, Shota ;
Hakiri, Shuhei ;
Ozeki, Naoki ;
Yokoi, Kohei .
ANNALS OF THORACIC SURGERY, 2016, 101 (05) :1877-1882
[10]   "How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question [J].
Guo, Huiru ;
Li, Hegen ;
Zhu, Lihua ;
Feng, Jiali ;
Huang, Xiange ;
Baak, Jan P. A. .
FRONTIERS IN ONCOLOGY, 2021, 11